Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation.
Scheen, André
2023 • In The Lancet Regional Health. Europe, 29, p. 100627
Scheen, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques ; Division of Clinical Pharmacology, Centre for Interdisciplinary Research on ; Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine,
Language :
English
Title :
Underuse of glucose-lowering medications associated with cardiorenal protection in type 2 diabetes: from delayed initiation to untimely discontinuation.
Scheen, A.J., Cardiovascular outcome studies in type 2 diabetes : comparison between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes Res Clin Pract 143 (2018), 88–100.
Brown, E., Heerspink, H.J.L., Cuthbertson, D.J., Wilding, J.P.H., SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet 398:10296 (2021), 262–276.
Scheen, A.J., Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 16:10 (2020), 556–577.
Kristensen, S.L., Rorth, R., Jhund, P.S., et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7:10 (2019), 776–785.
Davies, M.J., Aroda, V.R., Collins, B.S., et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetologia 65:12 (2022), 1925–1966.
Mahtta, D., Ramsey, D.J., Lee, M.T., et al. Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type 2 diabetes: insights from the department of Veterans Affairs. Diabetes Care 45:2 (2022), 372–380.
Khunti, K., Seidu, S., Kunutsor, S., Davies, M., Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis. Diabetes Care 40:11 (2017), 1588–1596.
Malik, M.E., Falkentoft, A.C., Jensen, J., et al. Discontinuation and reinitiation of SGLT-2 inhibitors and GLP-1R agonists in patients with type 2 diabetes: a nationwide study from 2013-2021. Lancet Reg Health Europe, 2023, 10.1016/j.lanepe.2023.100617 in press.
Khunti, K., Aroda, V.R., Bhatt, D.L., et al. Re-examining the widespread policy of stopping sodium-glucose cotransporter-2 inhibitors during acute illness: a perspective based on the updated evidence. Diabetes Obes Metabol 24:11 (2022), 2071–2080.
ElSayed, N.A., Aleppo, G., Aroda, V.R., et al. 16. Diabetes care in the hospital: standards of care in diabetes-2023. Diabetes Care 46:Suppl 1 (2023), S267–S278.
